abstract |
The present invention relates to steroid derivatives for use as medicaments. In particular, the present invention relates to an agent for the treatment of benign and / or malignant tumors, which is capable of interrupting interference in Wnt-signals, such as cell cycle arrest during G1 phase, and / or , 5-androstene-, 5-pregnenolone steroid derivatives or the corresponding saturated derivatives (androstane or pregnane-) in the manufacture of a medicament providing an angiostatinic effect. Examples of such steroid derivatives are Δ-5-androstene-17α-ol, androstene-17α-ol-pregnane-17α-ol or pregnane-17α-ol derivatives. In a further aspect, the present invention relates to 5-androstan-3β, 17α-diol or 5-androstene-17β-ol-3β-sulfate by contacting androstan-3βα-diol, an enzyme and a sulfotransferase. Providing the corresponding androstane derivative (17α-AEDS or 17-AADS); and combining 17α-AEDS or 17α-AADS with a suitable carrier; thereby as a ligand for peroxisome proliferator-activated receptor γ (PPARγ) A method for the manufacture of a medicament for the treatment of benign and / or malignant tumors and / or inflammatory conditions, comprising the step of making a medicament capable of acting. |